PierianDx, a St. Louis-based clinical genomics informatics company, closed a $27m Series B funding round.
The round was led by ATW Partners and SJF Ventures with participation from existing investors Health Catalyst Capital, Inova Health Systems, RTI International, and ARUP Laboratories.
Founded in 2014 out of Washington University in St. Louis, and led by Michael L. Sanderson, CEO, PierianDx provides a SaaS platform that enables the practice of clinical genomics as a standard of care for advanced molecular diagnostic labs.
The company is focused on advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories, and patients worldwide.
The company will use the funds to continue to expand operations and develop its solutions.